We engineer the best drug candidates by applying high-throughput screening systems and optimization techniques.
Science
Leveraging cutting-edge science and technology to identify and propel best-in-class biologics to the clinic.
Paragon employs a breadth of protein engineering technologies to perform biologics discovery and optimization. We have built a team of exceptional leaders in drug discovery and development who work with top-tier partners to develop transformative programs.
Pipeline
Fueling a pipeline of best-in-class therapies for a range of diseases.
Our business model centers on bringing therapies to patients as rapidly as possible—once a program or set of programs achieves significant progress, we enable their advancement to the clinic by launching spinout companies, engaging in partnerships with other biopharma companies, or continuing to shape their development in-house at Paragon. Our product pipeline demonstrates our progress, with the leading program in clinical trials less than two years from ideation.
Programs
Discovery
Ind-Enabling
Clinical
Rights/Partner
PR004 (APG777)
PR001 (APG808)
PR007 (APG990)
PR012 (APG222)
Rights/Partner
Apogee Therapeutics is the first company to spin out of Paragon in 2022. Apogee is advancing a pipeline of potentially best-in-class product candidates targeting clinically validated biology and well-established development pathways to address the needs of the millions of people living with immunological and inflammatory disorders.
Programs
Discovery
Ind-Enabling
Clinical
Rights/Partner
PR011 (SPY001)
PR010 (SPY002)
PR014 (SPY003)
PR015 (SPY004)
PR026 (SPY130)
PR022 (SPY120)
PR025 (SPY230)
Rights/Partner
Spyre Therapeutics is the second company formed around technology spun out of Paragon. Established in 2023, Spyre is advancing a pipeline of product candidates that maximize the efficacy, safety, and convenience of treatments for inflammatory bowel disease (IBD), combining best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to potentially transform the treatment paradigm.
Programs
Discovery
Ind-Enabling
Clinical
Rights/Partner
PR035 (ORKA001)
PR029 (ORKA002)
Rights/Partner
Oruka Therapeutics is the third company formed around technology developed by Paragon. Established in 2024, Oruka is advancing a pipeline of potentially best-in-class biologics that aim to redefine the standard of care for patients with chronic skin diseases, including plaque psoriasis.
Programs
Discovery
Ind-Enabling
Clinical
Rights/Partner
PR002
PR013
Rights/Partner
Undisclosed
Programs
Discovery
Ind-Enabling
Clinical
Rights/Partner
Multiple internal programs
Rights/Partner
Spinouts
Building successful companies to accelerate therapeutic impact.
We are committed to improving the patient experience through innovation. Our scientific approach and expertise have provided the foundation for several spinout companies devoted to bringing best-in-class treatments to patients living with chronic conditions.
ABOUT APOGEE THERAPEUTICS
Apogee Therapeutics is a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological and inflammatory disorders. Apogee is building a pipeline of product candidates targeting clinically validated biology and well-established development pathways. Based in San Francisco, CA, Apogee was founded in 2022 by Fairmount and Venrock Healthcare Capital Partners and is backed by leading healthcare investors. Visit their website for more details.
ABOUT SPYRE THERAPEUTICS
Spyre Therapeutics is a biotechnology company advancing a robust pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD. The company was founded in 2023 by Fairmount and is based in Waltham, MA. Visit their website for more details.
ABOUT ORUKA THERAPEUTICS
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as one or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. Visit their website for more details.
Team
Dedicated experts with a passion for improving health outcomes.
Paragon is led by a collaborative team of innovators with deep expertise in biologics engineering and development. Our collaboration with FairJourney Biologics expands the reach and capabilities of our team through dedicated antibody discovery experts and resources. Together, we are motivated to tackle some of the toughest disease areas and improve quality of life for patients.
Evan Thompson, Ph.D.
CHIEF OPERATING OFFICER
View Bio
Hussam Shaheen, Ph.D.
HEAD OF RESEARCH
View Bio
Keri Lantz
HEAD OF FINANCE
View Bio
Damon Banks, Ph.D., J.D.
HEAD OF LEGAL
View Bio
Jason Oh, Ph.D.
SENIOR VICE PRESIDENT OF BIOLOGY
View Bio
Shawn Russell, Ph.D.
SENIOR VICE PRESIDENT OF CHEMISTRY, MANUFACTURING, AND CONTROLS
View Bio
Neta Batscha
SENIOR VICE PRESIDENT OF CORPORATE STRATEGY AND OPERATIONS
View Bio
Michael Meehl, Ph.D.
SENIOR VICE PRESIDENT OF BIOLOGICAL RESEARCH
View Bio
Petros Psathas, Ph.D.
VICE PRESIDENT OF PRECLINICAL DEVELOPMENT
View Bio
Cyrus Stacey
VICE PRESIDENT OF QUALITY
View Bio
Joe Russo
EXECUTIVE DIRECTOR OF FINANCE PLANNING AND ANALYSIS
View Bio
Archit Sheth-Shah
SENIOR DIRECTOR OF PORTFOLIO STRATEGY
View Bio
Byron Kwan, Ph.D.
DIRECTOR OF BIOTHERAPEUTICS
View Bio
Danielle Malloy
DIRECTOR OF LEGAL OPERATIONS
View Bio
Daniel Rios, Ph.D.
DIRECTOR OF BIOLOGY
View Bio
Pamela Howley
DIRECTOR OF CHEMISTRY, MANUFACTURING, AND CONTROLS
View Bio
Yuqi Liu, Ph.D.
DIRECTOR OF PROTEIN SCIENCE
View Bio
Andrew Schirmer
Associate Director of Manufacturing
View Bio
M. Murshid Alam, Ph.D.
PRINCIPAL SCIENTIST
View Bio
Byong Ha Kang, Ph.D.
PRINCIPAL SCIENTIST
View Bio
Jake Milligan, Ph.D.
PRINCIPAL SCIENTIST
View Bio
Kevin Kramer, Ph.D.
Senior Scientist
View Bio
Rita Vaz, Ph.D.
SENIOR DIRECTOR OF PROGRAM AND ALLIANCE MANAGEMENT
View Bio
Soraia Oliveira, Ph.D.
Senior Project Manager for Antibody Discovery and Development
View Bio
Joana Ministro, Ph.D.
SENIOR PROJECT MANAGER FOR ANTIBODY DISCOVERY AND DEVELOPMENT
View Bio
Joana Vidal Silva
PROJECT MANAGER FOR ANTIBODY DISCOVERY AND DEVELOPMENT
View Bio
Mark Heffernan
SENIOR DIRECTOR AND CORPORATE CONTROLLER
View Bio
Melissa Donnarummo
Director of Project Accounting
View Bio
Stefanie (Stef) Feldmann
DIRECTOR OF BUSINESS OPERATIONS
View Bio
Lauren Gillis
DIRECTOR OF EXECUTIVE ADMINSTRATION
View Bio
James Nzukie
DIRECTOR OF FINANCE PLANNING AND ANALYSIS
View Bio
Sophia Medina
ADMINISTRATIVE ASSISTANT
View Bio
About Us
Paragon was founded by Fairmount in 2021 as the firm’s discovery engine for best-in-class biologics. Leveraging a dedicated in-house team of scientific experts in antibody development, as well as our partnership with FairJourney Biologics, Paragon pursues unique therapeutic concepts and enables their rapid proof-of-concept validation. Fairmount is dedicated to investing in promising new therapies developed by biotechnology and life science companies and works closely with the Paragon team to provide research and strategic direction.
News
The latest Paragon news and developments.
- All
- Paragon News
- Partner News
- Sort by
- Newest
- Oldest
- Paragon Therapeutics
- Spyre Therapeutics
- apogee Therapeutics
- Oruka Therapeutics
Join Us
Be a part of our innovative team.
We are excited about the future as we advance our state-of-the-art science. Come join our team and help us shape the next generation of biologic treatments.